| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
125,280,000 |
| Market
Cap: |
1.05(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.92 - $19.36 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 771 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Corbus Pharmaceuticals Holdings is focused on the development of immune modulators that will have application in disease states spanning from immuno-oncology to fibrosis. Co.'s pipeline includes anti-integrin monoclonal antibodies that block activation of Transforming growth factor B (TGFB) and small molecules that activate or inhibit the endocannabinoid system. Co.'s pipeline includes: anti-integrin monoclonal antibodies for the treatment of cancer and fibrosis that inhibit the activation of TGFB; cannabinoid receptor type 1 inverse agonists designed to treat obesity and related metabolic diseases; and lenabasum, a synthetic, oral molecule that activates cannabinoid receptor type 2.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,932,632 |
| Total Buy Value |
$0 |
$0 |
$0 |
$53,693,262 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
71,703 |
71,703 |
92,197 |
173,598 |
| Total Sell Value |
$1,057,883 |
$1,057,883 |
$1,218,685 |
$5,033,039 |
| Total People Sold |
4 |
4 |
6 |
6 |
| Total Sell Transactions |
5 |
5 |
10 |
16 |
| End Date |
2025-10-09 |
2025-07-08 |
2025-01-07 |
2024-01-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chen Bihua |
|
• • • |
2025-12-11 |
4 |
S |
$11.46 |
$344,012 |
I/I |
(30,029) |
2,344,971 |
|
17% |
|
| Cohen Yuval |
Chief Executive Officer |
• • – |
2025-10-27 |
4 |
AS |
$17.14 |
$153,797 |
D/D |
(8,973) |
138,187 |
|
-54% |
|
| Cohen Yuval |
Chief Executive Officer |
• • – |
2025-10-27 |
4 |
OE |
$4.26 |
$38,225 |
D/D |
8,973 |
147,160 |
|
- |
|
| Cohen Yuval |
Chief Executive Officer |
• • – |
2025-10-24 |
4 |
AS |
$17.01 |
$317,407 |
D/D |
(18,660) |
138,187 |
|
-53% |
|
| Cohen Yuval |
Chief Executive Officer |
• • – |
2025-10-24 |
4 |
OE |
$4.26 |
$79,492 |
D/D |
18,660 |
156,847 |
|
- |
|
| Moran Sean F. |
Chief Financial Officer |
• – – |
2025-10-24 |
4 |
AS |
$17.02 |
$220,937 |
D/D |
(12,981) |
73,313 |
|
-53% |
|
| Moran Sean F. |
Chief Financial Officer |
• – – |
2025-10-24 |
4 |
OE |
$4.26 |
$55,299 |
D/D |
12,981 |
86,294 |
|
- |
|
| Altmeyer Anne |
|
– • – |
2025-10-20 |
4 |
AS |
$20.50 |
$21,730 |
D/D |
(1,060) |
6,191 |
|
-57% |
|
| Altmeyer Anne |
|
– • – |
2025-10-20 |
4 |
OE |
$4.80 |
$5,088 |
D/D |
1,060 |
7,251 |
|
- |
|
| Ben Yong |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
7,583 |
|
- |
|
| Altmeyer Anne |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
6,191 |
|
- |
|
| Altmeyer Anne |
|
– • – |
2025-05-30 |
4 |
AS |
$7.25 |
$10,096 |
D/D |
(1,392) |
1,391 |
|
81% |
|
| Jenkins John Kenneth |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
4,833 |
|
- |
|
| Jenkins John Kenneth |
|
– • – |
2025-05-30 |
4 |
AS |
$7.35 |
$20,465 |
D/D |
(2,783) |
33 |
|
81% |
|
| Jacques Rachelle Suzanne |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
7,583 |
|
- |
|
| Kung Winston |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
10,366 |
|
- |
|
| Holmer Alan F |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
10,629 |
|
- |
|
| Hodgson Ian |
Chief Operating Officer |
• – – |
2025-03-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,977 |
|
37% |
|
| Smethurst Dominic |
Chief Medical Officer |
• – – |
2025-03-06 |
4 |
S |
$6.78 |
$43,330 |
D/D |
(6,393) |
70,807 |
|
-22% |
|
| Cohen Yuval |
Chief Executive Officer |
• • – |
2025-02-14 |
4 |
AS |
$8.76 |
$62,465 |
D/D |
(7,134) |
138,187 |
|
-6% |
|
| Moran Sean F. |
Chief Financial Officer |
• – – |
2025-02-14 |
4 |
AS |
$8.76 |
$24,446 |
D/D |
(2,792) |
73,313 |
|
-6% |
|
| Moran Sean F. |
Chief Financial Officer |
• – – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
76,105 |
|
- |
|
| Smethurst Dominic |
Chief Medical Officer |
• – – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
27,200 |
77,200 |
|
- |
|
| Cohen Yuval |
Chief Executive Officer |
• • – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
68,100 |
145,321 |
|
- |
|
| Cormorant Global Healthcare Master Fund, Lp |
|
• • • |
2024-09-20 |
4 |
B |
$17.48 |
$7,003,761 |
I/I |
350,000 |
2,375,000 |
0.01 |
-50% |
|
146 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.37 (4.6%) 
